Braskem is trading at R$4.15, down 5.03%, with the reason for the October 13 decline unconfirmed.
- No clearly confirmed new company announcement on October 13 directly explains the intraday move.
- Recent coverage cited an earlier UBS BB downgrade to sell and a lower R$3.75 price target, alongside concerns about debt and possible shareholder dilution; this does not establish todayβs cause.
- The broader U.S. market was nearly flat, so the supplied market context does not clearly explain the drop.